Morning Education SymposiaJump start your day! Hear leading authorities discuss important clinical developments and present a broad perspective of the topics, so you can gain complete understanding of the issues addressed. Sessions are peer-reviewed to ensure content balance. Sessions are held early in the morning and include breakfast.
Register for morning educational symposia on-site at the Philadelphia Marriott Downtown. Registration will take place prior to the sessions, from 5:30 am to 6:00 am, outside the respective meeting rooms. Registration will be granted on a first-come, first-served basis. Sessions will close when room capacity is reached. There will be no additional admittance to a session that has closed, so you are encouraged to come early and reserve your space There is no additional fee to attend a morning educational symposium, but you must be a registered attendee of CHEST 2008
Monday, October 27 Tuesday, October 28 Wednesday, October 29
Monday, October 27 New Evidence in the Prevention and Management of Thromboembolic Disorders This symposium will educate physicians and health-care practitioners on the latest evidence-based medicine on venous thromboembolism (VTE) and appropriate treatment guidelines associated with thromboembolic diseases. The focus will be on VTE diseases, including prevention, management, and treatment options. The target audience is pulmonologists, critical care specialists, cardiologists, cardiothoracic surgeons, and other health-care practitioners at the 2007 annual ACCP meeting. Objectives
Program Chair Faculty Supported by an educational grant from sanofi-aventis.
Evidence-Based Treatment for Pulmonary Arterial Hypertension in an Evolving Environment Pulmonary arterial hypertension (PAH) is a progressive cardiopulmonary vascular disease characterized by right ventricular failure, substantial morbidity, and high mortality. Effective management of PAH is enhanced by earlier recognition and early and aggressive management. This symposium will highlight the importance of early recognition and implementation of evidence-based guidelines for the treatment of PAH, as well as address future and emerging therapies for PAH. Case presentations and interactive discussion among the faculty will emphasize important teaching points. Objectives
Program Chair Faculty Supported by an unrestricted educational grant from Actelion Pharmaceuticals.
When Epidemics Collide: Sleep Disorders and COPD—What’s New and What Can We Do? COPD remains the only major cause of mortality with a rising incidence worldwide, and it is expected to become the third leading cause of death by 2020. Traditionally, the clinical staging of severity and the risk of mortality have relied on the measurement of FEV1. Staging criteria for COPD using percentage of predicted FEV1 values can be useful in predicting impairment in health-related quality of life. Comorbid conditions are common, and they negatively influence quality of life. An increasing concern with patients diagnosed with COPD is insomnia resulting from multiple arousals. Understanding sleep changes in patients with COPD depends upon a review of the oxyhemoglobin dissociation curve. When examining ventilation during sleep in patients with obstructive lung disease, a variety of pathophysiologic events take place. This session will review the literature and current research on sleep-related disorders in patients with obstructive lung disease, with an emphasis on patients with COPD. Objectives
Program Chair Faculty Supported by an educational grant from Takeda Pharmaceuticals North America, Inc.
COPD 2009 COPD is the fourth leading cause of chronic morbidity and mortality in the United States. Its prevalence and impact are increasing, and The World Bank and World Health Organization have projected it will rank fifth as a global burden of disease in 2020. The economic and public health impact of COPD is staggering because this chronic condition requires long-term care, frequent office visits, and the use of ED and hospital services. This session will provide an update on COPD based on the current literature. It also will provide a review of the results of new clinical trials, with an emphasis on the pressing need to have new therapies that control symptoms and prevent disease progression. Pharmacologic and nonpharmacologic measures will be presented to define how clinicians can best improve quality of care, including mandatory smoking cessation to slow the progression of lung function loss. New areas of research that may help guide COPD management in the future will be presented, as well. Objectives
Program Chair Faculty Supported by an unrestricted educational grant from GlaxoSmithKline.
Early Detection of COPD: A Clinical Controversy The use of spirometry for the early detection of COPD has been a topic of controversy since 1999 when CHEST published the National Lung Health Education Program (NLHEP) guidelines recommending office spirometry testing for all smokers over the age of 45 years. The benefits of drug therapy when the FEV1 is above 50% predicted are disputed, while only one in four patients with a new diagnosis of COPD has undergone spirometry testing to confirm any degree of airway obstruction. Two members of NLHEP will discuss the evidence for and against large national programs that provide screening or promote case-finding for COPD. Objectives
Program Chair Faculty Supported by an educational grant from AstraZeneca LP.
Tuesday, October 28 Patient-Focused Care in COPD COPD is a complex clinical syndrome that presents a combination of small airway abnormalities, emphysema, and systemic features. Pulmonologists, primary care physicians, and other professional medical team members are often called to manage patients with COPD in the setting of disease heterogeneity and associated comorbidities. As COPD morbidity becomes more prevalent, the need for better diagnostics, treatment options, and delivery systems is essential. This session will discuss comorbidities within the context of disease heterogeneity in COPD, generating an evolving approach to the optimal diagnostic and therapeutic algorithm for this complex condition. Objectives
Program Chair Faculty Supported by an educational grant from Novartis Pharmaceuticals Corporation.
Clinical Controversy: Pulmonary Embolism Treatment and Prophylaxis With New vs Old Heparins Particularly in the ICU, properties of the much-promoted, new subcutaneous injectable anticoagulants (low molecular weight heparins, fondaparinux) are perceived to carry important limitations, eg, long half-lives and questionable absorption in patients who are being underperfused. Moreover, supposed limitations of unfractionated heparin (the need for titration during pulmonary embolism treatment, risk of heparin-induced thrombocytopenia, etc) may not pose much real risk in settings where patients can be closely monitored. However, newer anticoagulants also are perceived to be more effective for venous thromboembolism (VTE) prophylaxis, an important advantage for the sickest patients. These patients may have impaired hemostasis and other increased comorbid bleeding risks if thrombosis occurs and full anticoagulation becomes necessary. The speakers will synthesize available data relating to prophylaxis and treatment of VTE to support their different viewpoints about when newer or older anticoagulants are preferred. There will be a special focus on the types of fragile patients in hospitals or clinics that pulmonary and critical physicians are most likely to encounter. Objectives
Program Chair Faculty Supported by an unrestricted educational grant from GlaxoSmithKline.
Asthma and COPD: Similarities and Differences COPD is often misdiagnosed, and people with COPD are commonly treated for asthma. Primary care physicians indicate that they prescribe similar medications for COPD and asthma, even though the appropriate treatments differ. First-line maintenance therapy for most patients with asthma is an inhaled corticosteroid, with the addition of bronchodilators, if needed, to control symptoms. However, bronchodilators are the first-line maintenance treatment for COPD. Treatment with inhaled corticosteroids is reserved only for patients with COPD that is not adequately managed with bronchodilators. This session will address common clinical problems, the overlap between asthma and COPD, and the pathophysiologic, diagnostic, and management similarities and differences between these disorders. Objectives
Program Chair Faculty Supported by an unrestricted educational grant from GlaxoSmithKline.
Clinical Implications of Sedation in Critical Care Experts in the field will provide up-to-date information on clinical areas of patient assessment and the use of tools to evaluate sedation, agitation, pain, and delirium; the pharmacologic use of sedative and analgesic agents; and delirium. Follow-up case study questions will reiterate information provided during the lectures. Objectives
Program Chair Faculty Supported by an educational grant from Hospira Worldwide, Inc.
Wednesday, October 29 New Anticoagulants The face of anticoagulation is changing. This symposium will educate physicians and health-care practitioners on the latest science related to new anticoagulants. While clinicians have relied on heparin and warfarin for decades, and more recently on low molecular weight heparins and pentasaccharide preparations, newer agents are in phase III trials. The parenteral factor Xa inhibitor, idraparinux, as well as oral direct thrombin inhibitors and factor Xa inhibitors, have been investigated in thousands of patients and are being, or will be, considered by the US Food and Drug Administration and the European Medicines Agency within the next few years. Based on the available clinical trial data thus far, important considerations will include the relative efficacy, safety, cost of these agents, as well as the potential for reversibility. These considerations will need to be translated into a way to select a specific agent for different prophylactic and therapeutic indications. Clinicians will need to know the advantages and disadvantages of these agents and how to use them in clinical practice. Will the heparins and coumadins be entirely replaced by new therapies? Objectives
Program Chair Faculty Supported by an educational grant from sanofi-aventis.
Controversies in Clinical Pulmonary Arterial Hypertension In the last several years, new therapeutic options for pulmonary hypertension have emerged. Nevertheless, clinicians treating patients with pulmonary hypertension are faced with important questions that this session will address. How should we use current guidelines when initiating therapy? What are the options and when should we escalate treatment? What are the differences between various therapeutic agents? This important debate will draw on experience from experts in pulmonary hypertension and will educate attendees on the subtleties of treating this devastating disease. This session will highlight the complexities of the disease and the therapeutic challenges that we face, especially with the multitude of agents available. Objectives
Program Chair Faculty Supported by an independent educational grant from Gilead Sciences Medical Affairs. |
||
 |
||
|
||
|
||
|
||
|